TQB2618 + toripalimab

TQB2618 + toripalimab is a combination of two monoclonal antibodies used in cancer immunotherapy clinical trials. **TQB2618** is a monoclonal antibody targeting T-cell immunoglobulin and mucin domain-containing protein 3 (**TIM-3**), a negative regulator of immune response implicated in tumor immune evasion. **Toripalimab** is a monoclonal antibody against programmed cell death protein 1 (**PD-1**), a well-established checkpoint inhibitor that unleashes anti-tumor immunity. When administered together, these drugs aim to enhance anti-tumor T cell activity through dual checkpoint inhibition, potentially leading to increased tumor response rates. The combination is under investigation for advanced malignancies, including **melanoma** and other solid tumors, primarily in clinical trials led by Chia Tai Tianqing Pharmaceutical Group[1][5].

Other names

TQB2618 injection + Toripalimab injection